

Supplemental Table 1 Impact of adapted SUV thresholds in PSMA PET on OS, PSA-PFS and PSA response

SUVmax threshold	No. of cePSMA- PET	No. of cePSMA- PET	criteria for cePSMA PET $\ominus$		PSA response (%) in cePSMA- PET	PSA response (%) in cePSMA- PET	<i>p value</i> ^a	Median PSA- PFS (mo) in cePSMA-PET	Median PSA- PFS (mo) in cePSMA-PET	HR	95% CI	<i>p value</i> ^a	Median OS (mo) in cePSMA-PET	Median OS (mo) in cePSMA-PET	HR	95% CI	<i>p value</i> ^a
	$\oplus$ patients	$\ominus$ patients	no lesion $\geq$ SUVmax threshold	≥ 1 lesion with SUVmax < 10	$\oplus$ patients	$\ominus$ patients		$\oplus$ patients	$\ominus$ patients				$\oplus$ patients	$\ominus$ patients			
45/50	47	60	46	14	53.2	38.3	0.1251	6.8	3.6	0.8	0.5-1.2	0.2	17.0	12.0	0.8	0.5-1.1	0.1
40	51	56	42	14	52.9	37.5	0.1087	6.2	3.5	0.8	0.5-1.2	0.2	17.0	11.0	0.8	0.5-1.1	0.2
35	56	51	37	14	55.4	33.3	0.0221	6.4	3.5	0.6	0.4-1.0	0.0272	18.5	11.0	0.6	0.4-0.9	0.0047
30	63	44	28	16	55.6	29.6	0.0078	6.4	3.4	0.6	0.4-0.9	0.0061	17.0	10.0	0.5	0.3-0.8	0.0008
25	72	35	16	19	52.8	28.6	0.0182	6.0	3.5	0.6	0.4-1.0	0.0284	16.0	10.0	0.5	0.3-0.8	0.0007
20	77	30	9	21	54.5	20.0	0.0012	6.0	3.2	0.5	0.3-0.9	0.0069	15.0	10.0	0.4	0.3-0.9	0.0007
10/15	78	29	0	29	55.1	17.2	0.0005	6.0	3.2	0.6	0.3-1.0	0.0113	16.0	9.5	0.5	0.3-0.8	0.0005
^a Significant <i>p</i> values are given in bold																	

CI confidence interval, HR hazard ratio, OS overall survival, PSA-PFS PSA progression-free survival

^aSignificant *p* values are given in bold